Natural language processing to develop a standardized lexicon for precision medicine in oncology.

IF 3.3 4区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Tianyi Wang, Kimberly Tsai, Steven S Kheloussi, Dana McCormick, Pamala A Pawloski
{"title":"Natural language processing to develop a standardized lexicon for precision medicine in oncology.","authors":"Tianyi Wang, Kimberly Tsai, Steven S Kheloussi, Dana McCormick, Pamala A Pawloski","doi":"10.18553/jmcp.2026.32.9-b.s2","DOIUrl":null,"url":null,"abstract":"<p><p>Precision medicine terminology is increasingly used across clinical, laboratory, payer, regulatory, and policy settings; however, distinct terminology may be applied interchangeably or inconsistently across stakeholders, and foundational concepts may not be uniformly understood across multidisciplinary audiences with varying levels of expertise. This misalignment may create confusion for stakeholders as they attempt to navigate guideline recommendations and payer coverage policies, potentially impacting patient access to testing and treatment. In 2025, AMCP held a 2-day partnership forum on the topic of advancing precision medicine in oncology. Forum participants recommended development of a consolidated lexicon of commonly used precision medicine terms to support clearer communication and foundational understanding across stakeholders and to clarify distinctions between related concepts. Nineteen definitions were ultimately generated using a natural language processing process, an artificial intelligence approach used to extract information and derive meaning from large text samples. A comprehensive literature review was first conducted to develop an index of publicly available precision medicine terminology sources. Natural language processing-based textual analysis was then used to systematically evaluate terminology usage patterns across the index, including both consistent and inconsistent usage of terms across sources. Draft definitions generated through this process were subsequently reviewed and refined by forum participants. The resulting lexicon included relevant terms related to (1) foundational concepts in precision medicine; (2) biological foundations and molecular variation; (3) biomarker and molecular testing; (4) testing technologies, specimen collection, and regulatory classification; and (5) testing approach. The objective of this work was to organize commonly used precision medicine terms into a single reference framework, a foundational precision medicine reference for managed care stakeholders, and to clarify distinctions between related concepts where appropriate.</p>","PeriodicalId":16170,"journal":{"name":"Journal of managed care & specialty pharmacy","volume":"32 9-b Suppl","pages":"S3-S16"},"PeriodicalIF":3.3000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13452051/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of managed care & specialty pharmacy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.18553/jmcp.2026.32.9-b.s2","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Precision medicine terminology is increasingly used across clinical, laboratory, payer, regulatory, and policy settings; however, distinct terminology may be applied interchangeably or inconsistently across stakeholders, and foundational concepts may not be uniformly understood across multidisciplinary audiences with varying levels of expertise. This misalignment may create confusion for stakeholders as they attempt to navigate guideline recommendations and payer coverage policies, potentially impacting patient access to testing and treatment. In 2025, AMCP held a 2-day partnership forum on the topic of advancing precision medicine in oncology. Forum participants recommended development of a consolidated lexicon of commonly used precision medicine terms to support clearer communication and foundational understanding across stakeholders and to clarify distinctions between related concepts. Nineteen definitions were ultimately generated using a natural language processing process, an artificial intelligence approach used to extract information and derive meaning from large text samples. A comprehensive literature review was first conducted to develop an index of publicly available precision medicine terminology sources. Natural language processing-based textual analysis was then used to systematically evaluate terminology usage patterns across the index, including both consistent and inconsistent usage of terms across sources. Draft definitions generated through this process were subsequently reviewed and refined by forum participants. The resulting lexicon included relevant terms related to (1) foundational concepts in precision medicine; (2) biological foundations and molecular variation; (3) biomarker and molecular testing; (4) testing technologies, specimen collection, and regulatory classification; and (5) testing approach. The objective of this work was to organize commonly used precision medicine terms into a single reference framework, a foundational precision medicine reference for managed care stakeholders, and to clarify distinctions between related concepts where appropriate.

自然语言处理为肿瘤精准医学开发标准化词汇。
精准医学术语越来越多地用于临床、实验室、付款人、监管和政策设置;然而,不同的术语可能在涉众之间互换或不一致地应用,并且具有不同专业水平的多学科受众可能无法统一理解基础概念。这种错位可能会给利益相关者带来困惑,因为他们试图导航指南建议和付款人覆盖政策,可能影响患者获得检测和治疗。2025年,AMCP举办了为期两天的合作伙伴论坛,主题是推进肿瘤精准医学。论坛与会者建议制定常用精准医学术语的统一词典,以支持利益相关者之间更清晰的沟通和基本理解,并澄清相关概念之间的区别。19个定义最终使用自然语言处理过程生成,这是一种用于从大量文本样本中提取信息和获取含义的人工智能方法。首先进行了全面的文献综述,以建立一个公开可用的精确医学术语来源的索引。然后使用基于自然语言处理的文本分析系统地评估整个索引中的术语使用模式,包括跨来源的术语一致和不一致的使用。通过这一进程产生的定义草案随后由论坛参与者审查和完善。由此产生的词典包括以下相关术语:(1)精准医学的基本概念;(2)生物学基础和分子变异;(3)生物标志物和分子检测;(四)检测技术、标本采集和监管分类;(5)测试方法。这项工作的目的是将常用的精准医学术语组织到一个单一的参考框架中,这是管理医疗利益相关者的基础精准医学参考,并在适当的地方澄清相关概念之间的区别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of managed care & specialty pharmacy
Journal of managed care & specialty pharmacy Health Professions-Pharmacy
CiteScore
3.50
自引率
4.80%
发文量
131
期刊介绍: JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书